Small molecule inhibitors of TLR4, i.e., NI-0101 [193] and Ibudilast [194], are being assessed in extrahepatic disease, and JKB-121, a weak TLR4 antagonist, is currently being assessed in NASH [195]: preliminary results do not support a significant therapeutic benefit of JKB-121, though the study was confounded by a notable improvement in liver inflammation within the placebo group. This evidence concerns the gene TLR4 and metabolic dysfunction-associated steatohepatitis.